The fine points of end points: phase II trials in lung cancer

Free article

Editorial

K A Gelmon. Ann Oncol. 1998 Oct.

Free article

. 1998 Oct;9(10):1045-6.

doi: 10.1023/a:1008429313403.

No abstract available

Comment on

Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer.
Sekine I, Kubota K, Nishiwaki Y, Sasaki Y, Tamura T, Saijo N. Sekine I, et al. Ann Oncol. 1998 Oct;9(10):1079-84. doi: 10.1023/a:1008473003445. Ann Oncol. 1998. PMID: 9834819
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
Vokes EE, Ansari RH, Masters GA, Hoffman PC, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PA, Golomb HM. Vokes EE, et al. Ann Oncol. 1998 Oct;9(10):1085-90. doi: 10.1023/a:1008432729754. Ann Oncol. 1998. PMID: 9834820 Clinical Trial.